China Anticipates Speeding Up R&D By Joining OECD As Observer - DIA China Conference
This article was originally published in PharmAsia News
Executive Summary
BEIJING - China's status as an observer country in the Organization for Economic Cooperation and Development will help the local contract research organization sector get faster access to the world's top biomedical markets for drugs developed and tested in China, said leaders at DIA's China conference May 19
You may also be interested in...
WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone
SHANGHAI - WuXi PharmaTech CEO Ge Li showed his disappointment about the terminated merger with Charles River Laboratories, stressed the near-term impact will be minor, and promised to continue development of WuXi's toxicology services, during an Aug. 2 earnings call
WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone
SHANGHAI - WuXi PharmaTech CEO Ge Li showed his disappointment about the terminated merger with Charles River Laboratories, stressed the near-term impact will be minor, and promised to continue development of WuXi's toxicology services, during an Aug. 2 earnings call
WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone
WuXi expects to have a full service toxicology operation in China in the next five years, which would have been accelerated by a merger with Charles River. By 2015, China is expected to gain more of the global toxicology service market projected to reach $150 million to $200 million.